FDA panel votes against approval of J&J arthritis drug

(Reuters) - The benefits of Johnson & Johnson's experimental rheumatoid arthritis drug sirukumab do not outweigh the risks and it should not be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday.